Figure 6
Figure 6. PF-04691502 inhibits anti-IgM– and CXCL12–induced signaling in Eμ-TCL1 murine cells. Eμ-TCL1 cells were removed from mice and grown in vitro. Eμ-TCL1 cells were treated with soluble (Sol) anti-IgM (5-15 minutes) (A) or 200 ng/mL CXCL12 (B) in the presence or absence of PF-04691502 (0.0025-2.5 μM), and the effects on downstream signaling (pAKTT308, pAKTS473, pS6KT389, pS6S235/236, and pERKT202/Y204) were investigated by immunoblotting. HSC70 was used as a loading control. (C) Viability of Eμ-TCL1 cells by PF-04691502 was evaluated by annexin V/PI assays and represented as percentage viable cells. (D) Migration was performed as previously described in Figure 5B. Error bars represent SEM. *P < .02.

PF-04691502 inhibits anti-IgM– and CXCL12–induced signaling in Eμ-TCL1 murine cells. Eμ-TCL1 cells were removed from mice and grown in vitro. Eμ-TCL1 cells were treated with soluble (Sol) anti-IgM (5-15 minutes) (A) or 200 ng/mL CXCL12 (B) in the presence or absence of PF-04691502 (0.0025-2.5 μM), and the effects on downstream signaling (pAKTT308, pAKTS473, pS6KT389, pS6S235/236, and pERKT202/Y204) were investigated by immunoblotting. HSC70 was used as a loading control. (C) Viability of Eμ-TCL1 cells by PF-04691502 was evaluated by annexin V/PI assays and represented as percentage viable cells. (D) Migration was performed as previously described in Figure 5B. Error bars represent SEM. *P < .02.

Close Modal

or Create an Account

Close Modal
Close Modal